| Description | Antibody 6F5H1L1 is a humanized mAb specifically binding to human PDCD1 (programmed cell death 1), well-known as PD-1. This anti-PDCD1 antibody can effectively block the binding of PD-1 and its ligand PD-L1. The parental murine monoclonal antibody (6F5) was generated in BALB/c mice by immunization with recombinant PD-1(ECD)-TEV-mFc. The binding activities of this antibody were measured by ELISA. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Immunogen | Recombinant PD-1 extracellular domain-TEV-mouse Fc fragment |
| Epitope | The extracellular domain |
| EC50 | 0.118 nM (indirect ELISA; immunogen: PD-1-mFc, 0.5 μg/mL) 0.979 nM (competitive ELISA; immunogen: PD-1-hFc, 0.5 μg/mL) |
| Isotype | Humanized IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | ELISA |
| Application Notes | The binding activities of this antibody were measured by ELISA. Competitive ELISA was used to determine the ability of humanized antibody 6F5H1L1 to compete with PD-L1 (0.3 μg/mL) for binding the antigen PD-1 (0.5 μg/mL). |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Post Translational Modification | Ubiquitinated at Lys-233 by the SCF(FBXO38) complex, leading to its proteasomal degradation (PubMed:30487606). Ubiquitinated via 'Lys-48'-linked polyubiquitin chains (PubMed:30487606). Tyrosine phosphorylated at Tyr-223 (within ITIM motif) and Tyr-248 (ITSM motif) upon ligand binding. Phosphorylation at Tyr-248 promotes the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. N-glycosylation at Asn-58 contains at least two N-acetylglucosamine units and one fucose (PubMed:28165004). N-glycosylation does not affect binding to nivolumab drug (PubMed:28165004). |
